Health Care & Life Sciences » Pharmaceuticals | Champions Oncology Inc.

Champions Oncology Inc. | Cash Flow

Fiscal year is May-April. All values USD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,406.00
13,140.00
10,446.00
6,884.00
1,476.00
Depreciation, Depletion & Amortization
213.00
214.00
156.00
168.00
360.00
Other Funds
3,896.00
2,772.00
2,629.00
2,730.00
1,451.00
Funds from Operations
3,297.00
10,154.00
7,661.00
3,986.00
335.00
Changes in Working Capital
163.00
522.00
1,196.00
1,146.00
1,561.00
Net Operating Cash Flow
3,460.00
9,632.00
6,465.00
2,840.00
1,226.00
Capital Expenditures
234.00
119.00
322.00
766.00
1,229.00
Sale of Fixed Assets & Businesses
-
5.00
-
-
3.00
Net Investing Cash Flow
234.00
114.00
322.00
766.00
1,226.00
Issuance/Reduction of Debt, Net
-
1,988.00
42.00
24.00
25.00
Net Financing Cash Flow
21.00
13,210.00
2.00
4,316.00
13.00
Net Change in Cash
3,697.00
3,464.00
6,785.00
710.00
2,439.00
Free Cash Flow
3,694.00
9,751.00
6,787.00
3,606.00
2,455.00
Change in Capital Stock
21.00
11,222.00
44.00
4,340.00
38.00
Exchange Rate Effect
24.00
-
-
-
-

About Champions Oncology

View Profile
Address
One University Plaza
Hackensack New Jersey 07601
United States
Employees -
Website http://www.championsoncology.com
Updated 07/08/2019
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.